DK0984955T3 - Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og 1-oxo-isoindoliner og fremgangsmåde til reduktion af TNF-alpha-niveauer - Google Patents

Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og 1-oxo-isoindoliner og fremgangsmåde til reduktion af TNF-alpha-niveauer

Info

Publication number: DK0984955T3
Authority: DK; Denmark
Prior art keywords: carbon atoms; hydrogen; alkyl; isoindolines; dioxopiperidin
Prior art date: 1997-05-30

Application number

DK98924959T

Other languages

English (en)

Inventor

George W Muller

David I Stirling

Roger Shen-Chu Chen

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-30

Filing date

1998-05-28

Publication date

2005-01-03

1998-05-28 Application filed by Celgene Corp filed Critical Celgene Corp

2005-01-03 Application granted granted Critical

2005-01-03 Publication of DK0984955T3 publication Critical patent/DK0984955T3/da

Links

MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 title 1
FPNJYPLJTAYAMP-UHFFFAOYSA-N 7a-(2,6-dioxopiperidin-3-yl)-3ah-isoindole-1,3-dione Chemical class C1=CC=CC2C(=O)NC(=O)C21C1CCC(=O)NC1=O FPNJYPLJTAYAMP-UHFFFAOYSA-N 0.000 title 1
108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title 1
PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
125000000217 alkyl group Chemical group 0.000 abstract 4
150000002431 hydrogen Chemical class 0.000 abstract 3
-1 m -phenylene Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000005605 benzo group Chemical group 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)

DK98924959T 1997-05-30 1998-05-28 Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og 1-oxo-isoindoliner og fremgangsmåde til reduktion af TNF-alpha-niveauer DK0984955T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4827897P	1997-05-30	1997-05-30
EP19980924959 EP0984955B1 (en)	1997-05-30	1998-05-28	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing tnf alpha levels
PCT/US1998/010886 WO1998054170A1 (en)	1997-05-30	1998-05-28	SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNFα LEVELS

Publications (1)

Publication Number	Publication Date
DK0984955T3 true DK0984955T3 (da)	2005-01-03

Family

ID=21953674

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04077432T DK1486496T3 (da)	1997-05-30	1998-05-28	Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og fremgangsmåde til reducering af TNF-a-niveauer
DK98924959T DK0984955T3 (da)	1997-05-30	1998-05-28	Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og 1-oxo-isoindoliner og fremgangsmåde til reduktion af TNF-alpha-niveauer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK04077432T DK1486496T3 (da)	1997-05-30	1998-05-28	Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og fremgangsmåde til reducering af TNF-a-niveauer

Country Status (25)

Country	Link
US (3)	US6395754B1 (da)
EP (3)	EP1486496B1 (da)
JP (2)	JP4307567B2 (da)
KR (1)	KR100526212B1 (da)
CN (3)	CN1258293A (da)
AT (2)	ATE275139T1 (da)
AU (1)	AU741982B2 (da)
CA (2)	CA2669481C (da)
CY (1)	CY1108348T1 (da)
CZ (1)	CZ299812B6 (da)
DE (2)	DE69839739D1 (da)
DK (2)	DK1486496T3 (da)
ES (3)	ES2309443T3 (da)
FI (1)	FI19992490A (da)
HK (1)	HK1072248A1 (da)
HU (2)	HU228769B1 (da)
MC (1)	MC225A7 (da)
NO (6)	NO322080B1 (da)
NZ (1)	NZ501429A (da)
PL (1)	PL193276B1 (da)
PT (2)	PT984955E (da)
RU (1)	RU2209207C2 (da)
SK (1)	SK163099A3 (da)
TR (4)	TR201005282T2 (da)
WO (1)	WO1998054170A1 (da)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6228879B1 (en)	1997-10-16	2001-05-08	The Children's Medical Center	Methods and compositions for inhibition of angiogenesis
US6429221B1 (en)	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US6518281B2 (en) *	1995-08-29	2003-02-11	Celgene Corporation	Immunotherapeutic agents
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) *	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ATE327228T1 (de) *	1997-11-18	2006-06-15	Celgene Corp	Substituierte 2-(2,6-dioxo-3-fluoropiperidine-3- yl)-isoindoline und ihre verwendung zum reduzieren des tnf-alpha spiegels
US5955476A (en) *	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
CA2321920C (en) *	1998-03-16	2010-05-25	Hon-Wah Man	2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
WO2000055134A1 (en)	1999-03-18	2000-09-21	Celgene Corporation	Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US7629360B2 (en)	1999-05-07	2009-12-08	Celgene Corporation	Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en)	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en) *	2000-11-30	2007-02-01	The Children's Medical Center Corporation	Synthesis of 4-Amino-Thalidomide enantiomers
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) *	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
WO2003086373A1 (en) *	2002-04-12	2003-10-23	Celgene Corporation	Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN102429908A (zh)	2002-05-17	2012-05-02	细胞基因公司	用于治疗和控制多发性骨髓瘤的方法及组合物
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
USRE48890E1 (en)	2002-05-17	2022-01-11	Celgene Corporation	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
MXPA04011310A (es) *	2002-05-17	2005-02-14	Celgene Corp	Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades.
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en) *	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
JP2006510606A (ja) *	2002-10-15	2006-03-30	セルジーン・コーポレーション	骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
US8404717B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (en)	2002-10-15	2008-03-19	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
MXPA05004182A (es) *	2002-10-24	2005-06-08	Celgene Corp	Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento, modificacion y manejo del dolor.
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP2006508950A (ja) *	2002-10-31	2006-03-16	セルジーン・コーポレーション	黄斑変性の治療用組成物
US20040091455A1 (en) *	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
TW200501945A (en)	2002-11-06	2005-01-16	Celgene Corp	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US8034831B2 (en) *	2002-11-06	2011-10-11	Celgene Corporation	Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) *	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20050086715A (ko) *	2002-11-18	2005-08-30	셀진 코포레이션	(-)-3-(3,4-디메톡시-페닐)-3-(1-옥소-1,3-디히드로-이소인돌-２-일)-프로피온아미드를 포함하는 조성물 및 그의 사용방법
AU2003294311B8 (en) *	2002-11-18	2008-06-05	Celgene Corporation	Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US7320992B2 (en)	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
UA83504C2 (en) *	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080027113A1 (en) *	2003-09-23	2008-01-31	Zeldis Jerome B	Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) *	2003-10-23	2009-11-03	Celgene Corporation	Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1684758A4 (en) *	2003-11-06	2009-02-18	Celgene Corp	METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
EP1692128A1 (en)	2003-11-19	2006-08-23	Signal Pharmaceuticals LLC	Indazole compounds and methods of use thereof as protein kinase inhibitors
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
KR101224262B1 (ko)	2004-03-22	2013-01-21	셀진 코포레이션	면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
US20050222209A1 (en) *	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
JP2007532642A (ja) *	2004-04-14	2007-11-15	セルジーン・コーポレーション	脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
MXPA06011798A (es) *	2004-04-14	2007-01-16	Celgene Corp	Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
CN101163489A (zh) *	2004-04-23	2008-04-16	细胞基因公司	用于治疗和控制肺高血压的包含免疫调节化合物的组合物及其使用方法
CA2565447A1 (en) *	2004-05-05	2005-12-01	Celgene Corporation	Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
KR20070057907A (ko) *	2004-09-03	2007-06-07	셀진 코포레이션	치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법
KR20070085454A (ko) *	2004-10-28	2007-08-27	셀진 코포레이션	중추신경계 손상의 치료 및 관리를 위하여 ｐｄｅ４조절제를 사용하는 방법 및 조성물
WO2006058008A1 (en) *	2004-11-23	2006-06-01	Celgene Corporation	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
CA2595711A1 (en) *	2005-01-25	2006-08-03	Celgene Corporation	Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
CN100383139C (zh)	2005-04-07	2008-04-23	天津和美生物技术有限公司	可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
US20060270707A1 (en) *	2005-05-24	2006-11-30	Zeldis Jerome B	Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
WO2007005972A1 (en) *	2005-06-30	2007-01-11	Celgene Corporation	Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US20070038298A1 (en) *	2005-06-30	2007-02-15	Sulner Joseph W	Repair of tympanic membrane using placenta derived collagen biofabric
US7928280B2 (en) *	2005-07-13	2011-04-19	Anthrogenesis Corporation	Treatment of leg ulcers using placenta derived collagen biofabric
US20070021762A1 (en) *	2005-07-13	2007-01-25	Qing Liu	Ocular plug formed from placenta derived collagen biofabric
ES2434946T3 (es)	2005-08-31	2013-12-18	Celgene Corporation	Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
PL1928492T3 (pl)	2005-09-01	2011-09-30	Celgene Corp	Immunologiczne zastosowania związków immunomodulujących do szczepionki i przeciwzakaźnego leczenia choroby
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
US20070066512A1 (en) *	2005-09-12	2007-03-22	Dominique Verhelle	Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
CN1939922B (zh) *	2005-09-27	2010-10-13	天津和美生物技术有限公司	可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
DK1957633T3 (da) *	2005-10-13	2014-03-17	Anthrogenesis Corp	Immunomodulation under anvendelse af placentale stamceller
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
JP2009521931A (ja) *	2005-12-29	2009-06-11	アントフロゲネシスコーポレーション	胎盤幹細胞を収集及び保存するための改善された組成物、及び該組成物の使用方法
US20080064876A1 (en) *	2006-05-16	2008-03-13	Muller George W	Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CL2007002218A1 (es)	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
WO2008021391A1 (en) *	2006-08-15	2008-02-21	Anthrogenesis Corporation	Umbilical cord biomaterial for medical use
RU2448101C2 (ru) *	2006-08-30	2012-04-20	Селджин Корпорейшн	5-замещенные изоиндолиновые соединения
US8877780B2 (en)	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
CA2660806C (en) *	2006-08-30	2015-06-16	Celgene Corporation	5-substituted isoindoline compounds
SI2066656T1 (sl)	2006-09-26	2012-06-29	Celgene Corp	Zamenjani derivati kinazolinona kot protitumorska sredstva
US20080131522A1 (en) *	2006-10-03	2008-06-05	Qing Liu	Use of placental biomaterial for ocular surgery
US8071135B2 (en)	2006-10-04	2011-12-06	Anthrogenesis Corporation	Placental tissue compositions
KR20210018526A (ko)	2006-10-06	2021-02-17	안트로제네시스 코포레이션	천연(텔로펩티드) 태반 콜라겐 조성물
CN101186611B (zh)	2006-11-15	2011-05-18	天津和美生物技术有限公司	可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
US10494607B2 (en) *	2007-02-12	2019-12-03	Celularity, Inc.	CD34+,CD45−placental stem cell-enriched cell populations
CN101657206B (zh)	2007-02-12	2013-07-03	人类起源公司	利用胎盘干细胞治疗炎性疾病
WO2009020590A1 (en)	2007-08-07	2009-02-12	Celgene Corporation	Methods for treating lymphomas in certain patient populations and screening patients for said therapy
SG176442A1 (en)	2007-09-26	2011-12-29	Celgene Corp	6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
NZ599825A (en)	2007-09-28	2014-10-31	Anthrogenesis Corp	Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2235213A2 (en)	2007-12-20	2010-10-06	Celgene Corporation	Use of micro-rna as a biomarker of immunomodulatory drug activity
US20090232796A1 (en) *	2008-02-20	2009-09-17	Corral Laura G	Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
EP3354646A1 (en)	2008-10-29	2018-08-01	Celgene Corporation	Isoindoline compounds for use in the treatment of cancer
WO2010093434A1 (en)	2009-02-11	2010-08-19	Celgene Corporation	Isotopologues of lenalidomide
EP2411506B1 (en)	2009-03-25	2018-11-07	Celularity, Inc.	Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
MX2011008554A (es)	2009-05-19	2011-10-06	Celgene Corp	Formulaciones de 4-amino-2-(2,6-dioxopiperidin-3-il) isoindolin-1,3-diona.
US20120134969A1 (en)	2009-05-25	2012-05-31	Hiroshi Handa	Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
CN101696205B (zh)	2009-11-02	2011-10-19	南京卡文迪许生物工程技术有限公司	3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
US8716252B2 (en)	2009-12-22	2014-05-06	Celgene Corporation	(Methylsulfonyl) ethyl benzene isoindoline derivatives and their pharmaceutical uses
MX337566B (es)	2010-01-05	2016-03-10	Celgene Corp	Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
RS58523B1 (sr)	2010-02-11	2019-04-30	Celgene Corp	Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
CA2794096A1 (en)	2010-04-07	2011-10-13	Celgene Corporation	Methods for treating respiratory viral infection
WO2012078492A1 (en)	2010-12-06	2012-06-14	Celgene Corporation	A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
US8969315B2 (en)	2010-12-31	2015-03-03	Anthrogenesis Corporation	Enhancement of placental stem cell potency using modulatory RNA molecules
JP6132773B2 (ja)	2011-01-10	2017-05-24	セルジーンコーポレイション	Ｐｄｅ４及び／又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体
CA3109687A1 (en)	2011-03-11	2012-09-20	Celgene Corporation	Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
US9090585B2 (en)	2011-03-28	2015-07-28	Deuterx, Llc	2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
MX2013012083A (es)	2011-04-18	2014-04-16	Celgene Corp	Biomarcadores para el tratamiento de mieloma multiple.
EP3096142A3 (en)	2011-04-29	2017-03-08	Celgene Corporation	Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP3443968A1 (en)	2011-06-01	2019-02-20	Celularity, Inc.	Treatment of pain using placental stem cells
WO2012177678A2 (en)	2011-06-22	2012-12-27	Celgene Corporation	Isotopologues of pomalidomide
US9884042B2 (en)	2011-09-14	2018-02-06	Celgene Corporation	Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
KR102035362B1 (ko)	2011-12-27	2019-10-22	셀진 코포레이션	(+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
EP2858667A1 (en)	2012-06-06	2015-04-15	Bionor Immuno AS	Hiv vaccine
WO2014004990A2 (en)	2012-06-29	2014-01-03	Celgene Corporation	Methods for determining drug efficacy using cereblon-associated proteins
JP2015524811A (ja)	2012-07-27	2015-08-27	セルジーンコーポレイション	イソインドリン−１，３−ジオン化合物の調製プロセス
US9221788B2 (en)	2012-08-09	2015-12-29	Celgene Corporation	Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
US9694015B2 (en)	2012-09-10	2017-07-04	Celgene Corporation	Methods for the treatment of locally advanced breast cancer
JP6359563B2 (ja)	2013-01-14	2018-07-18	デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ，ＬＬＣ	３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
AU2014215458A1 (en)	2013-02-05	2015-08-13	Anthrogenesis Corporation	Natural killer cells from placenta
EP2764866A1 (en)	2013-02-07	2014-08-13	IP Gesellschaft für Management mbH	Inhibitors of nedd8-activating enzyme
AU2014236597A1 (en)	2013-03-14	2015-09-24	Deuterx, Llc	3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014172429A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
WO2015007337A1 (en)	2013-07-19	2015-01-22	Bionor Immuno As	Method for the vaccination against hiv
WO2015200795A1 (en)	2014-06-27	2015-12-30	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
PT3214081T (pt)	2014-10-30	2020-08-31	Kangpu Biopharmaceuticals Ltd	Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização
HUE065109T2 (hu)	2015-06-26	2024-05-28	Celgene Corp	Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
US9809603B1 (en)	2015-08-18	2017-11-07	Deuterx, Llc	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017117118A1 (en)	2015-12-28	2017-07-06	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
ITUB20169994A1 (it)	2016-01-14	2017-07-14	Phf Sa	Nuove forme cristalline di farmaci immunomodulatori
WO2018102786A1 (en)	2016-12-03	2018-06-07	Juno Therapeutics, Inc.	Methods for modulation of car-t cells
PL3618842T3 (pl)	2017-05-01	2024-02-19	Juno Therapeutics, Inc.	Kombinacja terapii komórkowej i związku immunomodulującego
BR112019025403A2 (pt)	2017-06-02	2020-08-18	Juno Therapeutics Inc	artigos de fabricação e métodos para tratamento usando terapia celular adotiva
JP2020526194A (ja)	2017-06-29	2020-08-31	ジュノーセラピューティクスインコーポレイテッド	免疫療法薬と関連する毒性を評価するためのマウスモデル
WO2019067792A1 (en)	2017-09-28	2019-04-04	Celularity, Inc.	TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
WO2019089858A2 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Methods of assessing or monitoring a response to a cell therapy
BR112020008323A2 (pt)	2017-11-01	2020-11-03	Juno Therapeutics Inc	anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b
CN111372585A (zh)	2017-11-16	2020-07-03	C4医药公司	用于靶蛋白降解的降解剂和降解决定子
MA51184A (fr)	2017-12-15	2020-10-21	Juno Therapeutics Inc	Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
EP3755718A1 (en)	2018-02-21	2020-12-30	Celgene Corporation	Bcma-binding antibodies and uses thereof
CN111902141A (zh)	2018-03-26	2020-11-06	C4医药公司	用于ikaros降解的羟脑苷脂结合剂
EP3781156A4 (en)	2018-04-16	2022-05-18	C4 Therapeutics, Inc.	SPIROCYCLIC COMPOUNDS
WO2020051235A1 (en)	2018-09-04	2020-03-12	C4 Therapeutics, Inc.	Compounds for the degradation of brd9 or mth1
WO2020097403A1 (en)	2018-11-08	2020-05-14	Juno Therapeutics, Inc.	Methods and combinations for treatment and t cell modulation
EP3880669A1 (en)	2018-11-13	2021-09-22	Biotheryx, Inc.	Substituted isoindolinones
EP3880238A1 (en)	2018-11-16	2021-09-22	Juno Therapeutics, Inc.	Methods of dosing engineered t cells for the treatment of b cell malignancies
EP3886875B1 (en)	2018-11-30	2024-05-08	Juno Therapeutics, Inc.	Methods for treatment using adoptive cell therapy
EP3897636A4 (en)	2018-12-19	2022-09-07	Celgene Corporation	SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATING THEREOF
CN113453679A (zh)	2018-12-20	2021-09-28	C4医药公司	靶向蛋白降解
CA3123303A1 (en)	2019-01-29	2020-08-06	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
WO2020181232A1 (en)	2019-03-06	2020-09-10	C4 Therapeutics, Inc.	Heterocyclic compounds for medical treatment
WO2022152821A1 (en)	2021-01-13	2022-07-21	Monte Rosa Therapeutics Ag	Isoindolinone compounds
WO2023220655A1 (en)	2022-05-11	2023-11-16	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023220641A2 (en)	2022-05-11	2023-11-16	Juno Therapeutics, Inc.	Methods and uses related to t cell therapy and production of same
WO2023250400A1 (en)	2022-06-22	2023-12-28	Juno Therapeutics, Inc.	Treatment methods for second line therapy of cd19-targeted car t cells
WO2024097905A1 (en)	2022-11-02	2024-05-10	Celgene Corporation	Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3378763D1 (en) *	1982-04-02	1989-02-02	Takeda Chemical Industries Ltd	Condensed pyrrolinone derivatives, and their production
US4849441A (en) *	1986-12-25	1989-07-18	Kyowa Hakko Kogyo Co., Ltd.	Isoindolin-1-one derivative and antiarrhythmic agent
US4808402A (en) *	1987-05-29	1989-02-28	Northwestern University	Method and compositions for modulating neovascularization
DK24089D0 (da) *	1989-01-20	1989-01-20	Hans Bundgaard	Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
AU1531492A (en) *	1991-02-14	1992-09-15	Rockefeller University, The	Method for controlling abnormal concentration tnf alpha in human tissues
AU661299B2 (en) *	1991-04-17	1995-07-20	Grunenthal Gmbh	New thalidomide derivatives, method of manufacture and use thereof in medicaments
US6228879B1 (en)	1997-10-16	2001-05-08	The Children's Medical Center	Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en)	2000-11-01	2001-12-27	D'amato Robert	Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5629327A (en) *	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5463063A (en) *	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
DE4422237A1 (de) *	1994-06-24	1996-01-04	Gruenenthal Gmbh	Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
US5795368A (en) *	1996-03-01	1998-08-18	O.I. Corporation	Microtrap sample concentrator and methods of use
DE19613976C1 (de) *	1996-04-09	1997-11-20	Gruenenthal Gmbh	Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en)	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
ES2529190T3 (es) *	1996-07-24	2015-02-17	Celgene Corporation	2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
CA2262906C (en)	1996-08-12	2006-10-31	Celgene Corporation	Novel immunotherapeutic agents and their use in the reduction of cytokine levels
DK1586322T3 (da)	1996-11-05	2008-12-01	Childrens Medical Center	Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
US5955476A (en)	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) *	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
CA2321920C (en) *	1998-03-16	2010-05-25	Hon-Wah Man	2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6673828B1 (en)	1998-05-11	2004-01-06	Children's Medical Center Corporation	Analogs of 2-Phthalimidinoglutaric acid
SK12832001A3 (sk) *	1999-03-12	2002-01-07	Boehringer Ingelheim Pharmaceuticals, Inc.	Protizápalové látky, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
WO2000055134A1 (en)	1999-03-18	2000-09-21	Celgene Corporation	Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US7182953B2 (en)	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
MXPA02009665A (es)	2000-03-31	2005-09-08	Celgene Corp	Inhibicion de actividad de ciclooxigenasa-2.
US6458810B1 (en)	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en)	2000-11-30	2007-02-01	The Children's Medical Center Corporation	Synthesis of 4-Amino-Thalidomide enantiomers
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en)	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
EP1389203B8 (en)	2001-02-27	2010-03-10	The Governement of the United States of America, represented by The Secretary Department of Health and Human services	Analogs of thalidomide as angiogenesis inhibitors
WO2003014315A2 (en)	2001-08-06	2003-02-20	The Children's Medical Center Corporation	Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
WO2003086373A1 (en)	2002-04-12	2003-10-23	Celgene Corporation	Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7498171B2 (en)	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN102429908A (zh)	2002-05-17	2012-05-02	细胞基因公司	用于治疗和控制多发性骨髓瘤的方法及组合物
US7323479B2 (en)	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
MXPA05004182A (es)	2002-10-24	2005-06-08	Celgene Corp	Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento, modificacion y manejo del dolor.
US20050203142A1 (en)	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
JP2006508950A (ja)	2002-10-31	2006-03-16	セルジーン・コーポレーション	黄斑変性の治療用組成物
US20040091455A1 (en)	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en)	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
WO2005055929A2 (en)	2003-12-02	2005-06-23	Celgene Corporation	Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050143344A1 (en)	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
KR101224262B1 (ko)	2004-03-22	2013-01-21	셀진 코포레이션	면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
US20050222209A1 (en)	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
MXPA06011798A (es)	2004-04-14	2007-01-16	Celgene Corp	Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
CN101163489A (zh)	2004-04-23	2008-04-16	细胞基因公司	用于治疗和控制肺高血压的包含免疫调节化合物的组合物及其使用方法
CA2565447A1 (en)	2004-05-05	2005-12-01	Celgene Corporation	Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases

1997
- 1997-07-24 HU HU9903929A patent/HU228769B1/hu active Protection Beyond IP Right Term
1998
- 1998-05-28 PL PL337124A patent/PL193276B1/pl unknown
- 1998-05-28 EP EP20040077432 patent/EP1486496B1/en not_active Expired - Lifetime
- 1998-05-28 US US09/445,002 patent/US6395754B1/en not_active Expired - Lifetime
- 1998-05-28 DK DK04077432T patent/DK1486496T3/da active
- 1998-05-28 AT AT98924959T patent/ATE275139T1/de active
- 1998-05-28 DE DE69839739T patent/DE69839739D1/de not_active Expired - Lifetime
- 1998-05-28 KR KR10-1999-7011076A patent/KR100526212B1/ko not_active IP Right Cessation
- 1998-05-28 WO PCT/US1998/010886 patent/WO1998054170A1/en active Application Filing
- 1998-05-28 AU AU77012/98A patent/AU741982B2/en not_active Ceased
- 1998-05-28 EP EP19980924959 patent/EP0984955B1/en not_active Expired - Lifetime
- 1998-05-28 TR TR201005282T patent/TR201005282T2/xx unknown
- 1998-05-28 RU RU99128073A patent/RU2209207C2/ru not_active IP Right Cessation
- 1998-05-28 TR TR200000107T patent/TR200000107T2/xx unknown
- 1998-05-28 CZ CZ0427899A patent/CZ299812B6/cs not_active IP Right Cessation
- 1998-05-28 NZ NZ501429A patent/NZ501429A/en not_active IP Right Cessation
- 1998-05-28 ES ES04077432T patent/ES2309443T3/es not_active Expired - Lifetime
- 1998-05-28 PT PT98924959T patent/PT984955E/pt unknown
- 1998-05-28 CN CN98805614A patent/CN1258293A/zh active Pending
- 1998-05-28 CA CA 2669481 patent/CA2669481C/en not_active Expired - Fee Related
- 1998-05-28 CN CNA2006101262647A patent/CN1911927A/zh active Pending
- 1998-05-28 ES ES08009864T patent/ES2403102T3/es not_active Expired - Lifetime
- 1998-05-28 TR TR200801878T patent/TR200801878T2/xx unknown
- 1998-05-28 CN CNA2005100525903A patent/CN1680367A/zh active Pending
- 1998-05-28 TR TR200500299T patent/TR200500299T2/xx unknown
- 1998-05-28 DK DK98924959T patent/DK0984955T3/da active
- 1998-05-28 EP EP20080009864 patent/EP1956017B1/en not_active Expired - Lifetime
- 1998-05-28 PT PT04077432T patent/PT1486496E/pt unknown
- 1998-05-28 SK SK1630-99A patent/SK163099A3/sk unknown
- 1998-05-28 JP JP50090999A patent/JP4307567B2/ja not_active Expired - Fee Related
- 1998-05-28 DE DE1998625994 patent/DE69825994T2/de not_active Expired - Lifetime
- 1998-05-28 AT AT04077432T patent/ATE401319T1/de active
- 1998-05-28 ES ES98924959T patent/ES2229497T3/es not_active Expired - Lifetime
- 1998-05-28 HU HU0003217A patent/HU229578B1/hu not_active IP Right Cessation
- 1998-05-28 CA CA 2291218 patent/CA2291218C/en not_active Expired - Fee Related
1999
- 1999-11-23 NO NO19995751A patent/NO322080B1/no not_active IP Right Cessation
- 1999-11-23 FI FI992490A patent/FI19992490A/fi unknown
2002
- 2002-05-10 US US10/143,416 patent/US20020173658A1/en not_active Abandoned
2005
- 2005-01-14 US US11/035,817 patent/US7459466B2/en not_active Expired - Fee Related
- 2005-03-08 HK HK05102027A patent/HK1072248A1/xx not_active IP Right Cessation
- 2005-08-11 MC MC225K patent/MC225A7/xx unknown
2006
- 2006-03-30 NO NO20061455A patent/NO331367B1/no not_active IP Right Cessation
2008
- 2008-09-17 CY CY081101005T patent/CY1108348T1/el unknown
2009
- 2009-02-06 JP JP2009025981A patent/JP2009138009A/ja active Pending
- 2009-08-18 NO NO20092860A patent/NO332270B1/no not_active IP Right Cessation
2011
- 2011-11-08 NO NO20111536A patent/NO332271B1/no not_active IP Right Cessation
2012
- 2012-03-06 NO NO2012004C patent/NO2012004I2/no unknown
- 2012-03-20 NO NO20120330A patent/NO333641B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2291218A1 (en)	1998-12-03
US7459466B2 (en)	2008-12-02
MC225A7 (fr)	2006-03-07
KR20010013097A (ko)	2001-02-26
ATE401319T1 (de)	2008-08-15
SK163099A3 (en)	2000-06-12
CA2291218C (en)	2009-10-13
HUP9903929A3 (en)	2004-04-28
NO322080B1 (no)	2006-08-14
HK1072248A1 (en)	2005-08-19
CY1108348T1 (el)	2014-02-12
DK1486496T3 (da)	2008-09-08
CN1680367A (zh)	2005-10-12
PT1486496E (pt)	2008-07-30
EP1486496A1 (en)	2004-12-15
ES2229497T3 (es)	2005-04-16
KR100526212B1 (ko)	2005-11-03
JP2009138009A (ja)	2009-06-25
US6395754B1 (en)	2002-05-28
AU741982B2 (en)	2001-12-13
DE69825994D1 (de)	2004-10-07
US20020173658A1 (en)	2002-11-21
DE69825994T2 (de)	2005-09-29
NO2012004I1 (no)	2012-03-19
NO2012004I2 (no)	2013-05-06
EP0984955A1 (en)	2000-03-15
NO332270B1 (no)	2012-08-13
NZ501429A (en)	2001-11-30
TR200500299T2 (tr)	2005-06-21
FI19992490A (fi)	2000-01-27
NO333641B1 (no)	2013-07-29
CZ299812B6 (cs)	2008-12-03
HUP0003217A3 (en)	2002-03-28
TR201005282T2 (tr)	2011-06-21
CN1258293A (zh)	2000-06-28
CZ427899A3 (cs)	2000-05-17
NO995751D0 (no)	1999-11-23
NO332271B1 (no)	2012-08-13
JP2002501536A (ja)	2002-01-15
NO331367B1 (no)	2011-12-12
NO20092860L (no)	2000-01-28
EP1956017B1 (en)	2013-01-23
HU229578B1 (en)	2014-02-28
CA2669481C (en)	2011-10-04
NO20120330L (no)	2000-01-28
PL337124A1 (en)	2000-07-31
JP4307567B2 (ja)	2009-08-05
ES2309443T3 (es)	2008-12-16
NO20061455L (no)	2000-01-28
PL193276B1 (pl)	2007-01-31
WO1998054170A1 (en)	1998-12-03
CA2669481A1 (en)	1998-12-03
EP0984955B1 (en)	2004-09-01
TR200000107T2 (tr)	2000-07-21
NO995751L (no)	2000-01-28
PT984955E (pt)	2005-01-31
US20050131024A1 (en)	2005-06-16
CN1911927A (zh)	2007-02-14
HUP0003217A2 (hu)	2001-06-28
HU228769B1 (en)	2013-05-28
AU7701298A (en)	1998-12-30
TR200801878T2 (tr)	2008-08-21
RU2209207C2 (ru)	2003-07-27
ATE275139T1 (de)	2004-09-15
EP1956017A1 (en)	2008-08-13
DE69839739D1 (de)	2008-08-28
EP1486496B1 (en)	2008-07-16
NO20111536L (no)	2000-01-28
HUP9903929A2 (hu)	2000-05-29
ES2403102T3 (es)	2013-05-14

Publication	Publication Date	Title
DK0984955T3 (da)	2005-01-03	Substituerede 2-(2,6-dioxopiperidin-3-yl)-phthalimider og 1-oxo-isoindoliner og fremgangsmåde til reduktion af TNF-alpha-niveauer
DK1178967T3 (da)	2006-06-26	Quinolinderivater som inhibitorer af MEK-enzymer
HK1072770A1 (en)	2005-09-09	Bicyclic compound
HK1049004A1 (zh)	2003-04-25	含氮的環狀化合物和含有該化合物的藥用組合物
DE69332792T2 (de)	2004-01-15	4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
DK42589D0 (da)	1989-01-31	Anvendelse af arylamida(og arylthioamido)-azabicycloalkaner
ATE72436T1 (de)	1992-02-15	2-(methyl(4-piperidinyl)>-1,2,3,4-tetrahydro-9h pyrido(3,4-b>indolderivate, ihre herstellung und therapeutische verwendung.
EP0648740A4 (en)	1995-09-20	AMINO ACID AMIDE DERIVATIVE, HORTICULTURAL BACTERICIDE, AND PROCESS FOR PRODUCING THE SAME.
EA200000614A1 (ru)	2001-02-26	2,3-замещенные соединения индола в качестве ингибиторов сох-2
NO983493L (no)	1999-02-01	Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
DK452687D0 (da)	1987-08-28	Dihydropyridinforbindelser, isomere, isomerblandinger, optiske antipoder og racemater deraf, deres fremstilling og anvendelse som laegemidler
AP9901578A0 (en)	1999-06-30	Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
ATE240949T1 (de)	2003-06-15	Epoxysuccinamid-derivate oder ihre salze
UA100489C2 (en)	2013-01-10	Anthranilamide insecticides
YU43902A (sh)	2005-03-15	Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
TW350835B (en)	1999-01-21	Process for preparing nitroaniline derivatives
ATE261441T1 (de)	2004-03-15	Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
RS51051B (sr)	2010-10-31	Heksaciklična jedinjenja
ATE66475T1 (de)	1991-09-15	Aromatische thioaether.
ATE500241T1 (de)	2011-03-15	Phenyl- und pyridyl-piperidine mit tnf-wirkung
TH46046EX (th)	2001-07-03	"สารต้านทานเชื้อราประเภทไตรอาโซล"
ES2107376A1 (es)	1997-11-16	Nuevos derivados de pirimidona con actividad antifungica.
MY104164A (en)	1994-02-28	Heterocyclic compounds.